Orally administered devices could enable the systemic uptake of biologic therapeutics by engineering around the physiological barriers present in the gastrointestinal (GI) tract. Such devices aim to shield cargo from degradative enzymes and increase the diffusion rate of medication through the GI mucosa. In order to achieve clinical relevance, these designs must significantly increase systemic drug bioavailability, deliver a clinically relevant dose and remain safe when taken frequently. Such an achievement stands to reduce our dependence on needle injections, potentially increasing patient adherence and reducing needle-associated complications. Here we discuss the physical and chemical constraints imposed by the GI organs and use these to develop a set of boundary conditions on oral device designs for the delivery of macromolecules. We critically examine how device size affects the rate of intestinal obstruction and hinders the loading capacity of poorly soluble protein drugs. We then discuss how current orally administered devices could solve the problem of tissue permeation and conclude that these physical methods stand to provide an efficacious set of alternatives to the classic hypodermic needle.
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Introduction
Biologic drugs -including peptides, monoclonal antibodies, and nucleic acids -are revolutionizing the standard of care across many diseases. In general, patients must inject biologic drugs, rather than orally ingest them, because they degrade in the gastrointestinal (GI) space and do not easily permeate across biological barriers. However, administration via hypodermic needles requires training, causes pain, and leads to needle injuries as well as risk of infectious disease transmission [1] [2] [3] . In addition, needle-phobia, suffered by 10% of all individuals, may cause certain patients to forgo treatment or skip doses [4, 5] . These potential hazards affect clinicians' opinions of injectable medications, which manifest in lower prescription rates particularly in pediatric populations [6] . Here we discuss some of the fundamental challenges and realizable benefits of developing drugdevice combinations to enable the systemic delivery of biologics via the GI tract.
When compared to injectable drugs, physicians more commonly prescribe oral formulations acting in the same biologic pathway and for the same indications. This occurs even when the injectable drugs demonstrate clinically superior results. For example, in the treatment of type 2 diabetes, several clinical trials have shown that glucagon-like peptide-1 (GLP-1) receptor agonists (injectable) result in superior glycemic control and greater weight loss than dipeptidyl peptidase-4 (DPP-4) inhibitors (orally delivered), yet many patients and healthcare providers opt for the DDP-4 inhibitors because of the administration route [7] [8] [9] [10] . In 2016 DPP-4 inhibitor and GLP-1 agonist sales reached $10 billion and $4 billion, respectively [11] .
Efforts have been made for almost a century to address the problem of delivering biologics orally. In 1923 (2 years after the discovery of insulin), Harrison orally administered high concentrations of insulin in an alcohol solution with apparent success in only one of four patients [12] . Since, numerous scientists have attempted to increase the oral bioavailability of biologic drugs. The strategies used to optimize protein and peptide delivery focus on two main goals: tissue wall localization and enhanced permeation. Chemical modification strategies including mutagenesis, proteinylation, glycosylation, PEGylation and prodrugs as well as formulation strategies based on the use of absorption enhancers like nanoparticles, microspheres, liposomes and emulsions, have been used to increase the bioavailability to between 1% and 2% [13-16,17 ,18-21] . This threshold allowed for the development of oral vaccines using hydrogel-carriers and nanoparticle-based techniques to protect the antigen from the hostile environment of the GI tract [20, [22] [23] [24] . In this article we focus on new device-based strategies for drug delivery, which use physical means of tissue interaction coupled with chemical modifications in order to supply protein-based drugs with higher and narrower dose requirements than vaccines.
Understanding anatomy for successful drug delivery
The GI tract is comprised by the oral cavity, esophagus, stomach, small intestine and colon. The hostility of the GI tract, including its extreme pHs and high degradative enzymatic activity, hinders the delivery of many active pharmaceutical ingredients (APIs) (Figure 1 ). Furthermore, the physical properties of the GI organs including muscle contractions, variable membrane permeabilities, short residence times, and thick mucus coatings loaded with bacteria add additional challenges. When dealing with drug permeation it is important to ensure that the molecule overcomes the mucus coating and reaches the appropriate tissue layer to be taken up by the blood stream prior to enzymatic degradation [25] .
The high heterogeneity of the GI organs confers advantages and disadvantages for delivering drugs. The esophagus and the stomach provide quickly accessible delivery sites; however, rapid transit times through the esophagus and low pH conditions in the stomach add extra engineering constraints. In order to deliver an API in the stomach, it must avoid digestion, pass through the thickest mucus layer in the GI tract spanning 40-450 mm and transport para-cellularly (across the tight junctions) or trans-cellularly through the tissue [29] . The longer transit times and extended surface area in the small intestine favor its use as a delivery site. Additionally, specific areas in the organ, called Peyer's patches, are covered with less mucus allowing for a quicker absorption of hydrophobic formulations [16] ; however, targeting this organ delays drug uptake and still requires overcoming the presence of mucus and degradative enzymes. Finally, the colon provides residence times of up to 20 hours, yet the presence of stool and the bacteria-rich environment pose limitations to the delivery of biologics.
Devices to address biologic drug delivery
The need to overcome the challenges posed by the GI tract along with the growing demand for non-invasive methods have led the healthcare industry to invest in a range of novel technologies for the oral administration of biologics. These devices, expected to reach $3.83 billion in sales by 2020 [30] , resemble conventional capsules but carry small electronic and/or mechanical elements. Device size, which is directly related to drug loading capacity, acts as a major boundary condition towards designing an oral drug delivery device, and information gathered from clinical correlates helps inform dimensional restrictions. Additionally, device tissue localization and enhanced permeation or penetration represent significant challenges that need addressing.
Boundary conditions: Device size
Devices that target areas of the GI tract other than the oral cavity must adhere to strict size constraints. Researchers should limit the volume of a solid, non-disintegrating device to create something easily ingestible that poses a vanishingly rare risk of mechanical obstruction. To ensure the absence of clinical obstructive symptoms, a device must dissolve completely within approximately 1 day. The upper boundary for dimensions of ingestible devices has been established by clinical experience with video capsule endoscope (VCE) systems. VCEs, measuring 11 mm by 26 mm, allow for easy ingestion; however, an analysis of 2300 patients showed a retention rate of 1.3% [31] . In order to identify patients at risk of obstruction, doctors can prescribe a patency capsule of the same Schematic of the GI tract with corresponding pH ranges, average transit times and predominant protein degradative enzymatic activity [26] [27] [28] [29] .
size that degrades within 80 hours and tests for possible retention beforehand. If the capsule passes intact within 30 hours, then doctors consider the VCE safe to dose [32] . Drug delivery devices should also pass or degrade within a timescale consistent with this safely proven range of GI transit times [33] . However, even though this capsule size passes FDA regulations as an infrequently dosed diagnostic device, it is not practical for a therapeutic that could require regular administration.
The OROS system, an osmotic extended drug release capsule that leaves an indigestible shell approximately measuring 9 mm by 15 mm, provides a broader patient experience data set with respect to GI retention rates. Interestingly, the rate of GI retention is on the order of only one in 29 million in a sample size of almost 13 billion [34] . The OROS system has been on the market for dozens of years and is approved by the FDA for daily use. Shrinking a device mitigates obstruction risk, but size constraints raise the issue of another important boundary condition, drug loading.
Drug loading
In order for a drug delivery device to gain commercial use, it should deliver a relevant amount of API that must remain stable throughout the manufacturing process, on the shelf, and inside of the digestive tract. This poses a substantial challenge to the delivery of biologic macromolecules, which generally require a significant mass to exert a therapeutic effect, and are highly susceptible to degradation. While scientists have shown that certain vaccines remain stable in various shelf life temperature settings after immobilization in trehalose [35] , biologic molecules demonstrate a high vulnerability to degradation in the GI tract due to the presence of enzymes. A decrease in bioavailability by 50% requires a 100% increase of loaded API.
Delivering relevant doses of several biologic drugs in their current formulations will be very challenging due to volume constraints. Table 1 details the solution characteristics of several biologic drugs as well as the volume required to deliver a relevant injected dose. Capsules similar in size to the OROS system allow just under one milliliter of space for both the device and the loaded drug. The development of novel drug-device combinations will require careful consideration of the pharmacokinetics of this delivery route and moreover require significant formulation development to maintain the appropriate dose and activity of the API.
Tissue localization
The challenges associated with tissue wall localization stem from the constant motility and open geometries in the GI tract. The presence of degradative enzymes requires that all devices prevent elution of drug into the luminal space. Smooth muscle contractions from peristalsis constantly push luminal content through the upper GI tract causing nonlinear, convective flows up to 4 cm/s [37, 38] . Such flow patterns cause mixing, uniformly distributing a drug throughout the entire cavity and increasing its likelihood of binding with an enzyme. Since the diameter of the GI tract ranges anywhere from 2 cm in the small intestine up to 15 cm in the stomach, at least 80% of the drug will sit further than 1 mm away from the tissue wall at any given moment in a well-mixed system. This number climbs to 97% in the stomach. Because the k cat for pepsin is 45/s, and other degradation enzymes possess similar or faster velocities, drugs delivered to sites other than the tissue wall degrade without a chance for uptake.
Devices solve the tissue localization issue by taking advantage of the same concepts that prevent the use of traditional tablets. In particular, they target the small The following table contains a list of currently marketed biologic drugs and shows how the required dosage volumes change with molecular weight and solution strength. All dosages were calculated using a height of 180 cm and a weight of 70 kg [36] . Abbreviations: VIP, vasoactive intestinal peptide; TNF, tumor necrosis factor; RA, rheumatoid arthritis; CD, Crohn's disease; UC, ulcerative colitis.
intestine due to its smaller radius. For example, a carboxymethyl cellulose/poly(acrylic acid) hydrogel was reported to swell up against the tissue walls when exposed to near neutral pH, entirely filling the space inside of the small intestine with a drug loaded substance rather than chyme. Enzymatic degradation of the gel and diffusion of insulin into the small intestine yielded a bioavailability of 6.6% in rabbits [39] .
Other methods, such as mucoadhesion and nanostraw patterning, take advantage of the random flow patterns inside of the GI tract. Researchers designed these devices to stick to the tissue wall through chemical bonding or surface adhesion, and constant mixing ensures eventual contact with the mucosal barrier. Once attached to the tissue, these devices create privileged regions enabling insulin delivery with a concomitant hypoglycemic effect demonstrated in rats over the course of 8 hours. Because these devices rely on random flow patterns several do not attach correctly. On average around 25% of nanostraw devices land on the wrong side or never attach at all. While dose variability is inevitable in such a situation, researchers mitigate the concern by dosing several, sometimes thousands, of devices at a time [40,41 ,42 ]. Researchers should move away from a dependence on unpredictable forces in order to ensure tissue localization and standardized drug uptake profiles. Only in this way can they avoid the degree of variability observed by Harrison in his experiments reported in 1923.
Tissue permeation and penetration
Once drug formulations localize to the tissue wall, they must then pass through the mucus barrier of the GI tract to achieve systemic uptake. Devices aid in this process through both physical and biochemical means. Biochemical approaches such as polymer/liquid/inorganic nanocarriers, nanotubes, cell penetrating peptides, pore-forming proteins, vesicles, viral vectors, ligand conjugates and detergents chemically alter the cellular environment to open up new permeation pathways and can be delivered with anatomic selectivity through enterically coated devices [43] [44] [45] or smart ingestible pills like ChipRx and IntelliCap [46, 47] . Physical modes of delivery use devices to directly penetrate through tight junctions blocking drug uptake; methods include micro/nano-needles, ultrasound, microinjection, electroporation, cavitation, ballistics, scrapers, thermal enhancers, microjets and optoporation [41 ,48] . The newest of these technologies, microneedles, microjets, and ultrasound, all require quick and precise tissue localization.
Microneedles have been used over the last two decades to breach the stratum corneum and enhance permeation across the skin. The incorporation of this technology into an ingestible capsule could also increase tissue permeability in the GI tract. Scientists are currently developing a 'Robotic pill' consisting of drug-coated microneedles which will be pushed past the mucus into the small intestine epithelium via a gas based reaction between citric acid and sodium bicarbonate [49] . Since the small intestine has a mucus layer which is 200 mm thick and its wall measures approximately 1.2 mm, microneedles will have to be designed taking these parameters into consideration. These needles must penetrate the mucus layer while avoiding serious clinical complications such as perforation. Nevertheless, our group has previously shown that a capsule coated in 25 gauge metal microneedles protruding 5 mm from a device passes through the GI tract without evidence of mucosal damage [50 ] .
Other devices in development use transient methods of tissue interaction to avoid possible complications in the lower GI tract. For example, microjet injectors powered by gas reactions have delivered viral vectors in the oral cavity [51 ] . By propelling a jet into the buccal tissue of rabbits, antibodies pass through the disturbed mucus layer at high levels. Ultrasound has also been shown to enhance permeation of biologics in the GI tract [52 ,53] . Additionally, needle-free drug delivery systems have been used to deliver solution-based APIs by means of spring systems, lasers and energy propelled systems across the skin and to the oral mucosa [54] . In general, these physical penetrators significantly increase drug bioavailability, but they must localize to the tissue wall in order to work. Likely, a marketable version of an oral biologic device will be a combination of permeation enhancers, localization mechanisms, and machines used to cross the epithelial barrier of the GI tract.
Conclusion
While oral drug delivery devices have been shown to effectively release medications with a higher bioavailability than reformulations alone, there remain several challenges in the way of a marketable device. The oral route submits drugs to the heterogeneous GI environment inducing an uncertainty which complicates the dosage of drugs with narrow therapeutic indexes [12] . The new generation of orally administered devices avoids the uncontrollable forces in the GI tract and therefore lowers dosing variability by bypassing the gastric cavity and focusing on physical tissue wall interaction. There exists the potential for even greater standardized dosing if devices use their own forces for the process of tissue wall localization rather than relying on random fluid motion. Moreover, even the best devices provide bioavailabilities lower than 10% which necessitate large volumes dedicated to drug storage [55] , yet capsules on the order of 11 mm by 26 mm show rates of intestinal obstruction too high for daily dosing. Additionally, large capsules in general are associated with lower adherence rates in certain populations, especially children [56, 57] . Device miniaturization to maximize safety and drug reformulation to maximize API loading will be significant and essential development tasks. Scientists must focus on these efforts to finally realize the 100-year long quest for orally deliverable biologics.
Disclosures
All authors are co-inventors on multiple patent applications describing systems for the delivery of macromolecules via the gastrointestinal tract. G.T. and R.L. also receive consulting fees from Novo Nordisk.
